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Abstract
Objective
To quantify inequalities in zoster vaccine uptake by determining its association with socio-
demographic factors: age, gender, ethnicity, immigration status, deprivation (at Lower-layer
Super Output Area-level), care home residence and living arrangements.
Method
This population-based cohort study utilised anonymised primary care electronic health
records from England (Clinical Practice Research Datalink) linked to deprivation and
hospitalisation data. Data from 35,333 individuals from 277 general practices in
England and eligible for zoster vaccination during the two-year period (2013–2015)
after vaccine introduction were analysed. Logistic regression was used to obtain
adjusted odds ratios (aOR) for the association of socio-demographic factors with zoster
vaccine uptake for adults aged 70 years (main target group) and adults aged 79 years
(catch-up group).
Results
Amongst those eligible for vaccination, 52.4% (n = 18,499) received the vaccine. Socio-
demographic factors independently associated with lower zoster vaccine uptake in multivari-
able analyses were: being older (catch-up group: aged 79 years) aOR = 0.89 (95% confi-
dence interval (CI):0.85–0.93), care home residence (aOR = 0.64 (95%CI: 0.57–0.73)) and
living alone (aOR = 0.85 (95%CI: 0.81–0.90)). Uptake decreased with increasing levels of
deprivation (p-value for trend<0.0001; aOR most deprived versus least deprived areas =
0.69 (95%CI: 0.64–0.75)). Uptake was also lower amongst those of non-White ethnicities
(for example, Black versus White ethnicity: aOR = 0.61 (95%CI: 0.49–0.75)) but was not
lower among immigrants after adjusting for ethnicity. Lower uptake was also seen amongst
females compared to men in the catch-up group.
PLOS ONE | https://doi.org/10.1371/journal.pone.0207183 November 15, 2018 1 / 21
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Jain A, Walker JL, Mathur R, Forbes HJ,
Langan SM, Smeeth L, et al. (2018) Zoster
vaccination inequalities: A population based cohort
study using linked data from the UK Clinical
Practice Research Datalink. PLoS ONE 13(11):
e0207183. https://doi.org/10.1371/journal.
pone.0207183
Editor: Ivan Olier, Liverpool John Moores
University, UNITED KINGDOM
Received: January 30, 2018
Accepted: October 28, 2018
Published: November 15, 2018
Copyright: © 2018 Jain et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The data for this
study were obtained from the Clinical Practice
Research Datalink (CPRD) and are not owned or
collected by the authors. CPRD is a governmental,
not-for-profit research service that provides
primary care and linked data for public health
research. CPRD’s data governance and our own
license to use CPRD data do not allow us to
distribute or make available patient data directly to
other parties. Researchers can apply to the CPRD
for data access after having their study protocol
Conclusions
Inequalities in zoster vaccine uptake exist in England; with lower uptake among those of
non-White ethnicities, and among those living alone, in a care home and in more deprived
areas. Tailored interventions to increase uptake in these social groups should assist in real-
ising the aim of mitigating vaccination inequalities. As care home residents are also at higher
risk of zoster, improving the uptake of zoster vaccination in this group will also mitigate
inequalities in zoster burden.
Introduction
Zoster is caused by reactivation of latent varicella-zoster virus infection and mainly affects
older individuals. It is characterised by a painful dermatomal rash which may be followed by
persisting pain called post-herpetic neuralgia (PHN).[1] Amongst individuals aged�70 years
in England and Wales, an estimated ~53,000 cases of zoster occur annually of which ~27%
develop post-herpetic neuralgia.[2] To reduce zoster disease burden, the UK introduced a
national zoster vaccination programme (using a live vaccine: Zostavax manufactured by
Merck and Co. Inc., USA) in 2013, targeting individuals aged 70 years, with a catch-up pro-
gramme targeting older age groups.[3–5] The programme comprises vaccine administration
to individuals aged 70 years on 1 September of the corresponding year (the routine cohort).
For the catch-up programme, the vaccine was gradually rolled out in 2013/14 to individuals
aged 79 years on 1 September 2013, and in 2014/15 to those aged 78 and 79 years on 1 Septem-
ber 2014.[6, 7] Additionally, eligible individuals who missed the vaccine in previous years were
given the opportunity to get vaccinated in subsequent years. At introduction, uptake of the
programme was around ~62% in the routine cohort but has decreased to ~55% in 2015–2016.
[8] The reasons cited for this decline include difficulties experienced by general practice per-
sonnel who were busy with seasonal influenza vaccination, challenges in identifying individu-
als eligible for vaccination, insufficient follow-up of unvaccinated individuals and a potential
decline in vaccine knowledge amongst the eligible cohort.[6–8]
Monitoring and reducing inequalities in healthcare services or interventions is a statutory
requirement in the UK.[9] Inequalities in vaccine uptake, resulting in higher disease burden in
specific population groups, are well described.[10–13] Our 2017 systematic review and meta-
analysis investigated vaccine uptake amongst individuals aged�65 years in Europe and
reported lower seasonal influenza vaccine uptake amongst individuals living alone, those resid-
ing in more deprived areas and amongst immigrants.[12] Currently the national zoster post-
vaccination surveillance in England comprises collection of aggregated general practice level
data with information only on gender and limited ethnicity data.[8] The national zoster vac-
cine uptake for England was found generally to be higher amongst males, particularly in the
catch-up cohort.[8] The aggregated national zoster uptake data were also utilised in a 2017
study, which reported lower zoster vaccine uptake in deprived areas and amongst most non-
White ethnic groups.[14] However in this study, deprivation was assessed as an ecological fac-
tor and individuals were assigned ethnicity and vaccination status derived from the propor-
tions reported only at an aggregated general practice level.[14]
Ascertainment of the socio-demographic determinants of zoster vaccine uptake can provide
important information to public health professionals to address vaccination-related inequali-
ties and reduce zoster disease burden. We have recently shown that routinely collected clinical
and administrative information in the form of anonymised linked electronic health records
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are a useful resource to examine some of these socio-demographic factors, and these data can
be used to supplement the routine surveillance data.[15]
The primary objective of this study was therefore to identify the socio-demographic deter-
minants, of zoster vaccine uptake in England, using one of the world’s largest databases of gen-
eral practice electronic health records: the Clinical Practice Research Datalink (CPRD),[16]
with an overarching aim of mitigating vaccination inequalities amongst older individuals. The
nine socio-demographic factors of interest included: age, gender, ethnicity, immigration sta-
tus, deprivation (patient- and practice-small area-level), marital status, cohabitation, living
alone and care home residence. As a secondary objective, we also ascertained inadvertent zos-
ter vaccination of individuals whilst they were immunosuppressed, to quantify possible viola-
tions of the inclusion criteria.
Methods
Data source
The CPRD provides quality-assured anonymised primary care patients’ clinical, administrative
and lifestyle data representative of the UK population and covering approximately 7% of gen-
eral practices from England.[16, 17] Additionally, ~75% of CPRD general practices based in
England can be linked at an individual level to hospitalisation (Hospital Episode Statistics,
HES) data,[18] which provides information on all admissions to NHS hospitals, and at the
Lower-layer Super Output Area (LSOA) level [19] to deprivation data (Index of Multiple dep-
rivation (IMD) score).[19, 20] The English IMD score is a composite measure of relative depri-
vation for small geographic areas (LSOA), which cover an average population of 1500
individuals or 650 households.[19] This score is derived from using seven domains of depriva-
tion: education, employment, income, health and disability, crime, housing and living envi-
ronment with no definitive cut-off points for defining deprivation.[19] The validity of various
diagnoses recorded in CPRD was reported as high in a systematic review spanning a 21-year
study period.[21]
Study population
This 2-year cohort study from England spanned the period from 01/09/2013 to 31/08/2015,
the first two years after the zoster vaccine was introduced. To maintain patient anonymity,
CPRD data provide only year of birth for adult patients. This posed a problem in how to iden-
tify individuals who were eligible for zoster vaccination, which is determined by their age on a
specific date. The common convention of using the mid-year (1st July) to assign study partici-
pants’ day and month of birth would wrongly classify some individuals as eligible for zoster
vaccination. Importantly, the resulting unvaccinated group would comprise a mixture of indi-
viduals with possibly differing social factors: a) those eligible for vaccination who chose not to
be vaccinated and b) those ineligible on the grounds of age, thus potentially resulting in biased
effect estimates. To address this, we selected all individuals born in 1943 (or 1934 for catch-up
cohort), who would have been eligible for vaccination at some point during the 2-year follow-
up period as follows: those born in January-August 1943 would be eligible for the vaccine in
2013/14 or in 2014/15 if born September-December 1943; and determined vaccine uptake for
the 2-year study period. The study population therefore comprised individuals born in 1943
(the routine cohort) and in 1934 (the catch-up cohort), who were alive and registered on 01/
09/2013 (the start of the national programme) with a CPRD general practice that had agreed to
linkage to HES and IMD data and that met CPRD’s quality assurance criteria.[20] Start of fol-
low up was on 01/09/2013 and a minimum of five months of follow-up was required from
then (i.e. from September until the end of January, coinciding with the main part of the
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seasonal influenza vaccination season),[22] to ensure that individuals had sufficient opportu-
nity to receive zoster vaccination. Individuals who had any immunosuppressive conditions or
therapies at the start of follow up, that were contraindications to receiving the live zoster vac-
cine,[4] were excluded from analyses of the socio-demographic determinants of vaccine
uptake but included in descriptive analyses of inadvertent zoster vaccinations amongst immu-
nosuppressed individuals. All individuals with zoster vaccine codes prior to the start of
national programme and start of the study (01/09/2013) were also excluded.[23, 24] End of fol-
low-up was defined as the earliest of: (a) the end of the study (31/08/2015), (b) individuals’
transfer out date from the practice, (c) individuals’ date of death, or (d) the date data were last
collected from the practice.[20]
Defining the outcome
Zoster vaccination was determined in five different data files in CPRD: using product codes in
patients’ therapy files, immunisation codes in their immunisation files and Read codes (S1 Table)
in their clinical, referral and test files.[20] Additional immunisation and Read codes provided fur-
ther information on whether the vaccine was advised, refused or administered. When vaccination
data appeared in more than one file, we used an algorithm to assign vaccination date for each
individual and handle conflicting information; details are provided in the S1 Text and S1 Fig.
Exposure variables
The socio-demographic factors of interest were identified based on our previously developed
methodology of using CPRD linked to HES and IMD data.[15] The factors of interest, in addi-
tion to age and gender, included ethnicity, immigration status, care home residence, marital
status, cohabitation (defined as two individuals living as a couple) and living alone; code lists
are provided in S2 Table. The latter three social factors provided complementary information
about an individual’s living arrangements. Religion was not examined as our previous work
has shown it to be poorly recorded in CPRD data (<3% of older individuals).[15] For binary
socio-demographic variables, individuals without relevant codes were considered not to have
that characteristic. Ethnicity (five categories: White, South Asian, Black, Others and Mixed)
and immigration status (binary) were defined as factors that did not vary with time. Time-
varying factors included marital status (six categories: single, widow, married, divorced, sepa-
rated, partner uncategorised/other), cohabitation, living alone and care home residence
(binary variables). All the time-varying factors were determined at the start of follow up, with
any changes by the end of the 2-year follow-up period quantified and described. Actual IMD
scores are not made available to researchers by CPRD, to avoid identification of patients’ area
of residence, but all LSOA-level IMD scores in England are ranked (with scores in 2015 rang-
ing from 0.47 to 92.6) and then divided into quintiles for research use. Deprivation data (IMD
quintile at LSOA level: 2015, quintile 1 representing least deprived and quintile 5 the most
deprived quintile of deprivation) for both patient- and practice-LSOA-level l were available.
Practice- LSOA-level IMD quintiles were used if patient-level data were unavailable.
Other variables
At the initiation of the zoster vaccination programme, general practitioners (GPs) were
encouraged to co-administer zoster with seasonal influenza vaccine (SIV).[25] We therefore
investigated the concurrent administration of zoster vaccine with SIV. This was achieved by
identifying specific product codes, immunisation type codes and Read codes in CPRD (S3
Table) during the SIV campaign season (September-March)[26] of 2013/14 and 2014/15. Indi-
viduals who received SIV or/and zoster vaccine were quantified.
Identifying zoster vaccination inequalities in the UK using electronic health records
PLOS ONE | https://doi.org/10.1371/journal.pone.0207183 November 15, 2018 4 / 21
We also identified, throughout the study period, individuals who had immunosuppressive con-
ditions or treatments that were contraindications to receipt of zoster vaccine. This was done to
identify those who were eligible to receive the live zoster vaccine for the main analysis, and to
describe the extent of inadvertent administration of zoster vaccine to those with contraindications.
The immunosuppressive conditions and drugs included were those listed in the UK Green Book;
code lists (S2 Table) and algorithms used to identify these are described in the S4 Table.[4]
A past history of zoster was also ascertained using zoster or PHN codes from both CPRD
and HES (S5 Table) occurring before the start of follow-up (01/09/2013), or a first zoster code
of PHN occurring during follow-up.
Analyses
A complete case analysis using multivariable logistic regression was used to determine the
association of socio-demographic factors with zoster vaccine uptake, using adjusted odds
ratios (aOR) with 95% confidence intervals (CI). Logistic regression models were chosen to
address the problem of potential misclassification of individuals for vaccine eligibility based on
their date of birth and therefore the lack of information on person-time at risk for vaccination.
The exposure and outcome characteristics of individuals excluded from complete case primary
analysis because of missing data were described.
Gender and being a part of the routine or catch-up cohort (born in 1943 and 1934, respec-
tively) were considered to be a priori confounders of the socio-demographic factors of interest,
as well as potential determinants of zoster vaccine uptake. An existing conceptual framework
[27] was adapted to postulate the hierarchical inter-relationships between distal and proximate
social factors with the outcome (S6 Table).[28] Using this framework, socio-demographic factors
were added sequentially, as long as data sparsity or multicollinearity were not encountered. The
three multivariable models were as follows: Model 1 adjusted for a priori confounders (gender
and year of birth) immigration status and ethnicity; Model 2 additionally adjusted for depriva-
tion, and Model 3 additionally adjusted for the remaining socio-demographic factors. Standard
errors of the coefficients were compared in successive analyses to assess multicollinearity
between socio-demographic factors. Likelihood ratio tests were conducted for hypothesis testing
unless otherwise indicated. Linear trends, if appropriate, were also examined for ordered cate-
gorical variables such as patient- and practice-LSOA-level IMD. The catch-up programme is dif-
ferent from the routine programme, and differences between the two age groups (routine and
catch-up) in the effect of one sociodemographic factor (gender) on vaccine uptake have been
reported by the national surveillance data.[6, 7] We therefore investigated whether the effects of
the social factors varied between the two age cohorts by adding interaction terms to the models.
In sensitivity analyses, we repeated multivariable analyses: 1) restricted to individuals who
were followed up for the entire study period of two years; 2) adding the social factors that had
been excluded due to multicollinearity issues; 3) replacing the status of the time-varying factors
to that ascertained at the end of follow-up instead of at the start of follow-up, and 4) including
past history of zoster in the final multivariable model as a potential mediator of some of the
socio-demographic factors.
Additionally, inadvertent zoster vaccination amongst individuals with immunosuppressive
conditions or therapies was also described.
Data were analysed using Stata 14 (StataCorp, College Station, TX, USA).
Ethics
Approval was sought and obtained from the Observational/Interventions Research Ethics
Committee of the London School of Hygiene and Tropical Medicine (Reference: 11910) and
Identifying zoster vaccination inequalities in the UK using electronic health records
PLOS ONE | https://doi.org/10.1371/journal.pone.0207183 November 15, 2018 5 / 21
from the Independent Scientific Advisory Committee (ISAC) of the Medicines and Healthcare
products Regulatory Agency (reference:16_168). The ISAC protocol was made available to the
reviewers of this paper.
Results
A total of 39,120 individuals born in 1943 or 1934 and with no evidence of prior zoster vacci-
nation were registered with a CPRD practice, which had consented to linkages, on 01/09/2013
(Fig 1). The percentage of individuals who had relevant codes for binary socio-demographic
variables (as described in the Methods) was 1.8% for immigration status, 9.2% for care home
residence, 63.6% for cohabitation and 72.4% for living alone variable. After excluding those
who had contraindications to zoster vaccine at the start of follow-up or less than 5 months fol-
low-up, 35,333 individuals from 277 practices were considered for the primary analysis (Fig 1).
Primary analysis
A slight majority of the participants in the primary analysis (Table 1) were female. A higher
proportion was born in the year 1943 (the main target group), were from a White ethnic back-
ground, and were cohabiting (living as a couple) and/or not living alone. Data for marital
Fig 1. Zoster vaccine uptake study flow chart.
https://doi.org/10.1371/journal.pone.0207183.g001
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status were missing for 37.1% participants (Table 1) and practice-LSOA-level IMD was used to
replace the missing patient-LSOA-level IMD for 0.07% (n = 26) participants. A past history of
zoster was present for 11.4% of participants (Table 1).
Table 1. Baseline characteristics of the study population: Comparison of individuals with minimum follow-up of 5 months and 24 months.
Variables Primary analysisa N = 35333 from 277 practices, vaccine
uptake = 18499 (52.4%)
N (%) registered with their practice for �6months on 01/
09/2013 = 34828 (98.6%)
Median duration (months) of registration on 01/09/2013
(IQR):
255.8 (IQR 137–402.4)
Sensitivity analysisb N = 21137 from 178 practices, vaccine
uptake = 12173 (57.6%)
N (%) registered with their practice for �6months on 01/
09/2013 = 20848 (98.6%)
Median duration (months) of registration on 01/09/2013
(IQR):
263.8 (IQR 145–396.1)
Total (column %) Received zoster vaccine (row %) Total (column %) Received zoster vaccine (row %)
Gender Male 16633 (47.1%) 8859 (53.3%) 9829 (46.5%) 5763 (58.6%)
Female 18700 (52.9%) 9640 (51.6%) 11308 (53.5%) 6410 (56.7%)
Year of birth 1943 21458 (60.7%) 11452 (53.4%) 13011 (61.6%) 7580 (58.3%)
1934 13875 (39.3%) 7047 (50.8%) 8126 (38.4%) 4593 (56.5%)
Immigration status Not immigrant 34821 (98.6%) 18270 (52.5%) 20891 (98.8%) 12052 (57.7%)
Immigrant 512 (1.4%) 229 (44.7%) 246 (1.2%) 121 (49.2%)
Ethnicity White 30052 (85.1%) 16244 (54.1%) 18044 (85.4%) 10709 (59.3%)
South Asian 669 (1.9%) 304 (45.4%) 269 (1.3%) 136 (50.6%)
Black 380 (1.1%) 147 (38.7%) 172 (0.8%) 89 (51.7%)
Other 262 (0.7%) 107 (40.8%) 138 (0.7%) 68 (49.3%)
Mixed 86 (0.2%) 36 (41.9%) 46 (0.2%) 25 (54.3%)
Missing 3884 (11%) 1661 (42.8%) 2468 (11.7%) 1146 (46.4%)
Patient-LSOA-level IMD~# Least deprived 9313 (26.4%) 5230 (56.2%) 5521 (26.1%) 3429 (62.1%)
2 8692 (24.6%) 4670 (53.7%) 5096 (24.1%) 2959 (58.1%)
3 7520 (21.3%) 3884 (51.6%) 4644 (22%) 2645 (57%)
4 5828 (16.5%) 2890 (49.6%) 3595 (17%) 1950 (54.2%)
Most deprived 3980 (11.3%) 1825 (45.9%) 2281 (10.8%) 1190 (52.2%)
Practice-LSOA-level IMD Least deprived 6184 (17.5%) 3479 (56.3%) 3190 (15.1%) 1922 (60.3%)
2 7979 (22.6%) 3952 (49.5%) 4994 (23.6%) 2711 (54.3%)
3 7407 (21%) 3849 (52%) 4157 (19.7%) 2464 (59.3%)
4 6455 (18.3%) 3488 (54%) 4040 (19.1%) 2321 (57.5%)
Most deprived 7308 (20.7%) 3731 (51.1%) 4756 (22.5%) 2755 (57.9%)
Care home� No 34133 (96.6%) 17976 (52.7%) 20509 (97%) 11851 (57.8%)
Yes 1200 (3.4%) 523 (43.6%) 628 (3%) 322 (51.3%)
Living alone� No 25525 (72.2%) 13738 (53.8%) 15419 (72.9%) 9122 (59.2%)
Yes 9808 (27.8%) 4761 (48.5%) 5718 (27.1%) 3051 (53.4%)
Cohabiting� No 15352 (43.4%) 7316 (47.7%) 8899 (42.1%) 4691 (52.7%)
Yes 19981 (56.6%) 11183 (56%) 12238 (57.9%) 7482 (61.1%)
Marital status� Single 497 (1.4%) 232 (46.7%) 295 (1.4%) 148 (50.2%)
Married/Civil 6495 (18.4%) 3502 (53.9%) 3959 (18.7%) 2372 (59.9%)
Widow/er 1537 (4.4%) 800 (52%) 872 (4.1%) 508 (58.3%)
Divorced 516 (1.5%) 246 (47.7%) 304 (1.4%) 163 (53.6%)
Separated 143 (0.4%) 64 (44.8%) 93 (0.4%) 50 (53.8%)
Partner other/ uncategorised 13091 (37.1%) 7465 (57%) 8028 (38%) 4969 (61.9%)
Missing 13054 (36.9%) 6190 (47.4%) 7586 (35.9%) 3963 (52.2%)
History of zoster� No 31319 (88.6%) 16286 (52%) 18732 (88.6%) 10721 (57.2%)
Yes 4014 (11.4%) 2213 (55.1%) 2405 (11.4%) 1452 (60.4%)
aThose with immunosuppressing condition at start of follow-up excluded with minimum follow-up > = 5 months LSOA Lower-layer Super Output Area IMD Index of
Multiple Deprivation: a composite measure of relative deprivation for LSOA-level (details in the text) IQR interquartile range ~ 26 and #2 patients with missing patient-
LSOA-level IMD were replaced with practice-LSOA-level IMD for primary and secondary analyses respectively
bThose with immunosuppressing condition at start of follow-up excluded with minimum follow-up > = 24 months
�at start of follow-up
https://doi.org/10.1371/journal.pone.0207183.t001
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Of the total participants considered for the primary analysis, zoster vaccine was adminis-
tered to 18,499 (52.4%) individuals. Uptake amongst the main target group (those born in
1943) was 53.4% compared to 50.8% amongst the catch-up cohort (individuals born in 1934).
Nearly half (n = 17,527) of the participants received both zoster vaccine and SIV (Fig 2); of
these, only 36.8% (n = 6455) got both vaccines on same date (Fig 2), however the majority
(86.8%, n = 16,066) received zoster vaccination during the influenza campaign period (Sep-
tember-March)[26] of 2013/2014 and 2014/2015. Amongst 79.8% (n = 28,192) of the partici-
pants who received SIV, 73.3% (n = 20,685) received SIV in both the 2013/2014 and 2014/2015
campaign periods while 22.4% (N = 6,323) received SIV only in 2013/2014, and 4.2%
(N = 1,184) only in 2014/2015 season (data not shown).
A decision was made to drop marital status from the multivariable analyses, due to a large
proportion of individuals with missing data for this variable. Thus, in the subsequent complete
case analysis, only patients with missing ethnicity data (N = 3884, 11%) were excluded. This
resulted in a final study population of 31,449 (89%) individuals, amongst whom the zoster vac-
cine uptake was 53.5% (Fig 1). Comparison of individuals included (n = 31,449) and excluded
(n = 3884) from the complete case analysis due to missing ethnicity data is available in S7
Table. Briefly, excluded individuals were more likely to be in the main target cohort, and to be
from less deprived patient- and practice-level deprivation areas, and were less likely to be care
home residents, to have evidence that they were an immigrant or to have past history of zoster.
The excluded group was also less likely to be vaccinated for zoster.
Time-varying exposures at the start and end of follow-up remained largely unchanged for
98.8% individuals included in the complete case analysis (S8 Table).
a) Minimally adjusted model. In the analysis adjusted for a priori confounders (gender
and year of birth), there was strong evidence of an association between higher zoster vaccine
uptake and male gender, with uptake 10% higher compared to females (Table 2). There was
also evidence of lower vaccine uptake amongst the catch-up cohort, immigrants, those of non-
White ethnicity, care home residents, those living alone and those not cohabiting, with
Fig 2. Zoster and seasonal influenza vaccine uptake amongst study participants.
https://doi.org/10.1371/journal.pone.0207183.g002
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reduced odds of between 12% (being in the catch-up cohort) to 46% (Black ethnicity) (all p val-
ues<0.001, Table 2)). There was also strong evidence for a linear trend (p for trend<0.0001)
for decreasing vaccine uptake with increasing patient-LSOA-level deprivation (IMD) score,
the most deprived group having 34% lower odds of uptake compared to the least deprived
Table 2. Multivariable analyses- social factors associated with zoster vaccine uptake complete case analysis: Individuals with minimum follow-up of 5 monthsa.
Minimally
adjusted for year
of birth & gender
OR (95% CI)
P value~
(PT)
Model 1 additionally
adjusted for
immigration status &
ethnicity OR (95% CI)
P value~ Model 2 additionally
adjusted for patient-
LSOA-level IMD OR
(95% CI)
P value~
(PT)
Model 3 adjusted
for all variables
unless indicated
OR (95% CI)
P value~
(PT)
Gender Male 1.10 (1.05–1.15) 0.0001 1.09 (1.05–1.14) 0.0001 1.09 (1.04–1.14) 0.0001 1.08 (1.04–1.13) 0.0005
Female 1 1 1 1
Year of birth 1943 (main
target
group)
1 1 1 1
1934 (catch-
up cohort)
0.88 (0.84–0.92) <0.0001 0.88 (0.84–0.92) <0.0001 0.87 (0.84–0.91) <0.0001 0.89 (0.85–0.93) <0.0001
Immigration
status
Not
immigrant
1 1 1 1
Immigrant 0.71 (0.59–0.85) 0.0002 0.91 (0.75–1.11) 0.36 0.94 (0.77–1.15) 0.55 0.94 (0.77–1.14) 0.52
Ethnicity White 1 1 1 1
South Asian 0.70 (0.60–0.82) <0.0001 0.73 (0.61–0.86) <0.0001 0.73 (0.62–0.86) <0.0001 0.72 (0.61–0.85) <0.0001
Black 0.54 (0.44–0.67) 0.55 (0.44–0.67) 0.61 (0.49–0.75) 0.61 (0.49–0.75)
Other 0.58 (0.45–0.75) 0.59 (0.46–0.76) 0.60 (0.47–0.77) 0.61 (0.47–0.78)
Mixed 0.61 (0.40–0.94) 0.61 (0.40–0.94) 0.63 (0.41–0.96) 0.62 (0.40–0.96)
Patient-LSOA-
level IMD#
Least
deprived
1 Not in model 1 1
2 0.92 (0.86–0.98) <0.0001 0.92 (0.86–0.98) <0.0001 0.92 (0.87–0.98) <0.0001
3 0.85 (0.79–0.90) (<0.0001) 0.85 (0.80–0.91) (<0.0001) 0.86 (0.81–0.92) (<0.0001)
4 0.77 (0.72–0.83) 0.78 (0.73–0.84) 0.80 (0.74–0.86)
Most
deprived
0.66 (0.61–0.71) 0.67 (0.62–0.73) 0.69 (0.64–0.75)
Practice-
LSOA-level
IMD
Least
deprived
1 Not in model Not in model# Not in model#
2 0.76 (0.71–0.82) <0.0001
3 0.86 (0.80–0.93)
4 0.94 (0.87–1.01)
Most
deprived
0.81 (0.75–0.87)
Care home� No 1 Not in model Not in model 1
Yes 0.66 (0.58–0.74) <0.0001 0.64 (0.57–0.73) <0.0001
Living alone� Not living
alone
1 Not in model Not in model 1
Yes living
alone
0.85 (0.81–0.89) <0.0001 0.85 (0.81–0.90) <0.0001
Cohabiting� No 0.73 (0.70–0.77) <0.0001 Not in model Not in model Not in model#
Yes 1
aThose with immunosuppressing condition at start of follow-up excluded (Number of patients = 31449 vaccine uptake = 16,838 (53.5%)) OR odds ratio CI confidence
interval ~ likelihood ratio test PT P value for linear trend LSOA Lower-layer Super Output Area IMD Index of Multiple Deprivation # 19 patients with missing patient-
LSOA-level IMD were replaced with practice-LSOA-level IMD
�at start of follow-up
# excluded due to multicollinearity issues
https://doi.org/10.1371/journal.pone.0207183.t002
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group. Non-linear decreases in uptake were seen for practices in more deprived areas
(Table 2).
b) Multivariable analyses. After additionally adjusting the minimally adjusted model for
immigration status and ethnicity (Multivariable Model 1, Table 2), no appreciable changes in
effect estimates were observed, except lower uptake amongst immigrants was no longer appar-
ent after adjustment for ethnicity, with no evidence of collinearity between the two variables.
As patient- and practice-LSOA-level IMD were considered to be correlated, and as social fac-
tors relevant at an individual level were more of interest, only patient-LSOA-level IMD was
added to Model 2. No noticeable changes in effect estimates between Model 1 and Model 2
were observed, and the strong evidence of linear trend of lower uptake with increasing depri-
vation score seen in minimally adjusted analysis was still evident (p<0.001) in this model. Sim-
ilarly, living alone status and cohabitation were closely correlated, and so living alone was
added to the final multivariable model (Model 3), along with care home residence. Again, the
previously observed associations of lower uptake with living alone and residing in care home
persisted in this model; individuals living alone and those residing in care home had 15% and
36% decreased odds of uptake, respectively (Table 2). The effect estimates for other variables
were unchanged.
There was evidence that the effect of male gender, patient-LSOA-level IMD and care home
residence varied with age (Table 3). Analyses showed that the increase in vaccine uptake
among males was restricted to the catch-up cohort, and that the effects of care home status and
(to a lesser extent) increasing deprivation on lower vaccine uptake were more marked in the
catch-up cohort compared to the routine cohort.
Sensitivity analyses
There were no appreciable differences between the baseline characteristics of individuals with
follow-up for the entire 2-year study period and those included in primary analysis (follow-up
period of�5 months) (Table 1). The results of multivariable analyses for those with longer fol-
low up were similar to those from primary analysis except there was some attenuation in the
association of ethnicity with vaccine uptake; individuals of Other ethnicities had 31% reduced
odds (versus 39% in primary analysis) of uptake compared to those of White ethnicity in this
model (Table 4).
Substitution of cohabitation status instead of living alone, practice- LSOA-level IMD
instead of patient-LSOA-level IMD, excluding individuals with immunosuppressive condi-
tions at the end as opposed to start of follow-up (S9 Table) and determining care home status
at the end instead of start of follow-up (Table 4 sensitivity analyses) did not change the find-
ings. Individuals with a past history of zoster had 12% higher odds of uptake (Table 4), but
inclusion of past zoster in the multivariable model made little difference to the other effect
estimates.
To assess the impact of excluding individuals from the complete case analysis, a further
exploratory analysis was conducted, by re-running the minimally adjusted analysis for the
entire study population (N = 35,333) with follow-up�5 months including those with missing
data on ethnicity (S10 Table). Comparing the minimally adjusted model with that of primary
analysis revealed no noticeable differences in effect estimates. As the zoster vaccination pro-
gramme is delivered through primary care in England, the effect of clustering at practice-level
was also examined in an additional sensitivity analysis, using a multivariable (Model 3 in
Table 2) logistic regression model with random effects (S11 Table). Although there was evi-
dence for clustering within practices (with a p value <0.001 for the likelihood ratio test of an
intra-cluster correlation coefficient of 0), the effect estimates in the random effects model were
Identifying zoster vaccination inequalities in the UK using electronic health records
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Table 3. Interaction between age and social factors.
Gender Total
N (column
%)
Zoster vaccinations N (row
%)
Stratum-specific adjusted# OR for zoster vaccination
(95%CI)
P-value for
interaction�
Main target
group
Males 9059 (48.4%) 4977 (54.9%) 1.00 (0.95–1.06) <0.0001
Females 9677 (51.6%) 5303 (54.8%) 1
Catch-up
cohort
Males 5786 (45.5%) 3156 (54.5%) 1.22 (1.13–1.31)
Females 6927 (54.5%) 3402 (49.1%) 1
Immigration status Total
N (column
%)
Zoster vaccinations N (row
%)
Stratum-specific adjusted# OR for zoster vaccination
(95%CI)
P-value for
interaction�
Main target
group
Not immigrant 18432
(98.4%)
10139 (55%) 1 0.93
Immigrant 304 (1.6%) 141 (46.4%) 0.93 (0.73–1.19)
Catch-up
cohort
Not immigrant 12527
(98.5%)
6478 (51.7%) 1
Immigrant 186 (1.5%) 80 (43%) 0.95 (0.70–1.29)
Ethnicity Total
N (column
%)
Zoster vaccinations N (row
%)
Stratum-specific adjusted# OR for zoster vaccination
(95%CI)
P-value for
interaction�
Main target
group
White 17878
(95.4%)
9907 (55.4%) 1 0.73
South Asian 423 (2.3%) 202 (47.8%) 0.75 (0.61–0.91)
Black 211 (1.1%) 79 (37.4%) 0.55 (0.41–0.72)
Other 170 (0.9%) 69 (40.6%) 0.57 (0.42–0.78)
Mixed 54 (0.3%) 23 (42.6%) 0.61 (0.35–1.05)
Catch-up
cohort
White 12174
(95.8%)
6337 (52.1%) 1
South Asian 246 (1.9%) 102 (41.5%) 0.68 (0.52–0.89)
Black 169 (1.3%) 68 (40.2%) 0.70 (0.51–0.96)
Other 92 (0.7%) 38 (41.3%) 0.67 (0.44–1.03)
Mixed 32 (0.3%) 13 (40.6%) 0.64 (0.32–1.31)
Patient-LSOA-level
IMD
Total
N (column
%)
Zoster vaccinations N (row
%)
Stratum-specific adjusted# OR for zoster vaccination
(95%CI)
P-value for
interaction�
Main target
group
Least deprived 4781 (25.5%) 2766 (57.9%) 1 0.07
2 4514 (24.1%) 2520 (55.8%) 0.93 (0.85–1.00)
3 4033 (21.5%) 2226 (55.2%) 0.91 (0.83–0.99)
4 3160 (16.9%) 1658 (52.5%) 0.83 (0.76–0.91)
Most deprived 2248 (12%) 1110 (49.4%) 0.75 (0.68–0.83)
Catch-up
cohort
Least deprived 3261 (25.7%) 1837 (56.3%) 1
2 3208 (25.2%) 1732 (54%) 0.92 (0.83–1.01)
3 2677 (21.1%) 1342 (50.1%) 0.80 (0.72–0.88)
4 2119 (16.7%) 1024 (48.3%) 0.76 (0.68–0.84)
Most deprived 1448 (11.4%) 623 (43%) 0.62 (0.55–0.70)
Care home
residence
Total
N (column %)
Zoster vaccinations N (row
%)
Stratum-specific adjusted# OR for zoster vaccination
(95%CI)
P-value for
interaction�
(Continued)
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very similar to those from the primary analysis except for weaker evidence of reduced uptake
among two of the non-White ethnicities (South Asian and Mixed ethnicity, S11 Table).
Inadvertent zoster vaccinations
Of the 19,330 in the total study population who received vaccination (Fig 1), 3% (n = 596)
received zoster vaccine whilst immunosupressed.[4] Of these 596 patients, 28 (4.7%)
patients had more than one immunosuppressive condition at the time of vaccination. The
maximum number of immunosuppressive conditions at time of vaccination was three. The
most common immunosuppressive condition (n = 445) during which the patients received
zoster vaccine was cancer chemotherapy or radiotherapy, followed by patients taking other
immunosuppressive medications (n = 69), patients with leukemia, lymphoma, myeloma,
other plasma cell dyscrasias (n = 49), treatment with immunosuppressive dose of oral corti-
costeroid (n = 28), cellular immune deficiency (n = 25), solid organ transplant (n = 9) and
HIV (n = 1). None of the patients received zoster vaccination during the immunosuppres-
sive phase of a stem cell or bone marrow transplant.
Discussion
To the best of our knowledge, this is the first study to quantify the inequalities in the uptake of
zoster vaccine, administered in a national vaccination programme, using anonymised elec-
tronic health records. This large 2-year population based study from England revealed that
lower zoster vaccine uptake was independently associated with being a part of the catch-up
cohort, non-White ethnicity, residing in a care home, living alone, and not cohabiting (living
as a couple). A graded inverse association of patient-level deprivation with vaccine uptake was
also observed. Lower uptake was also seen amongst females in the catch-up cohort, and the
effects of care home residence and deprivation were more marked among the older catch-up
group.
Table 3. (Continued)
Gender Total
N (column
%)
Zoster vaccinations N (row
%)
Stratum-specific adjusted# OR for zoster vaccination
(95%CI)
P-value for
interaction�
Main target
group
No 18217 (97.2%) 10021 (55%) 1 0.0008
Yes 519 (2.8%) 259 (49.9%) 0.80 (0.67–0.95)
Catch-up
cohort
No 12097 (95.2%) 6328 (52.3%) 1
Yes 616 (4.8%) 230 (37.3%) 0.53 (0.45–0.63)
Living alone Total
N (column %)
Zoster vaccinations N (row
%)
Stratum-specific adjusted# OR for zoster vaccination
(95%CI)
P-value for
interaction�
Main target
group
Not living alone 14005 (74.7%) 7860 (56.1%) 1 0.22
Yes living alone 4731 (25.3%) 2420 (51.2%) 0.83 (0.78–0.89)
Catch-up
cohort
Not living alone 8791 (69.1%) 4618 (52.5%) 1
Yes living alone 3922 (30.9%) 1940 (49.5%) 0.89 (0.82–0.96)
# Final Model 3 from Table 2 (Number of patients = 31449 vaccine uptake = 16,838 (53.5%)) OR odds ratio CI confidence interval
�likelihood ratio test LSOA Lower-layer Super Output Area IMD Index of Multiple Deprivation
https://doi.org/10.1371/journal.pone.0207183.t003
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Strengths and limitations
Strengths of the study include the large sample size, and linkages to hospitalisation data which
provided additional information about socio-demographic factors as well as zoster vaccine
contraindications. For multivariable analysis, a hierarchical approach using conceptual frame-
work, enabled appropriate interpretation of effect estimates.[28] The NHS zoster vaccination
programme is administered via general practice only and thus capture of vaccination is likely
to be good. Additionally, our previous methodological study investigating ascertainment of
socio-demographic factors in linked CPRD data showed that the distribution of factors such as
ethnicity, not living alone, cohabitation and care home residence for individuals aged�65
years was comparable to the distribution in the 2011 English Census.[15]
The study limitations include potential misclassification of both socio-demographic factors
and the zoster vaccination recording. Our categorisation of individuals without a relevant
codes for a binary socio-demographic variable as not having the characteristic could have
introduced errors; if this misclassification was non-differential with respect to vaccine uptake,
this may have underestimated the effect estimates in this study. However, our previous meth-
odological study showed good capture of socio-demographic factors in CPRD data when com-
pared to the 2011 English Census.[15] Similarly, certain immunosuppressive treatments such
as biological agents, which are mainly prescribed in a hospital setting, may not be completely
captured in these primary care data. An additional issue is that some individuals may have
changed exposure status over time. Ideally, person-time at risk to estimate vaccination rates
would have been preferable but unavailability of complete dates of birth in CPRD precluded
this ascertainment. However, factors ascertained at start of follow-up remained unchanged for
98.8%-99.9% individuals at the end of follow-up and sensitivity analyses to assess the impact of
the time-varying factors reassuringly revealed similar results to the primary analysis. There
was also potential for bias resulting from the complete case analysis (owing to missing ethnic-
ity information) which led to exclusion of data from 11% of the study population. Further
assessment of this revealed that effect estimates from the minimally adjusted models for indi-
viduals for the entire study population (after dropping ethnicity) had no appreciable differ-
ences to those obtained from the complete case analysis. Lack of recording of marital status
prevented investigation of its association with zoster vaccine uptake, but other closely related
variables for living arrangements such as cohabitation and living alone were available.
Other factors indicative of socio-economic status of an individual and associated with vac-
cine uptake amongst older individuals, as reported by our systematic review,[12] such as
income, education, and occupation could not examined in this study as these factors were
unavailable in CPRD. However, the association of deprivation using IMD quintiles for both
patient- and practice-LSOA-level could be assessed in this study.
It is also feasible that individuals who see their GPs more frequently may have greater
opportunity to be offered vaccination. Thus, it is possible that healthcare utilisation may be a
potential mediating variable for the association between socio-demographic factors such as
deprivation, male gender (in the catch-up cohort) or ethnicity and zoster vaccine uptake. If
this were the case, adjusting for this mediating variable could attenuate the association between
some of the socio-demographic factors and vaccine uptake.
Although we were able to examine whether there was evidence of clustering at practice-
level, lack of information on practice-level variables (other than practice-LSOA-level-IMD)
prevented further investigation of this. It is possible that variations in certain general practice-
level characteristics, for example staffing levels, opening hours, and call/recall processes, could
have affected implementation of the zoster vaccine programme for all zoster vaccine-eligible
patients in that practice. These general practice-level data were unavailable in CPRD and
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therefore we could not determine to what extent the lower uptake we found in specific groups
related to lack of opportunity to be vaccinated rather than individual choice not to come for-
ward for vaccination. However, it is notable that practice-level clustering had little impact on
most of the effect estimates studied other than some of the estimates for ethnicity. Future stud-
ies assessing the effects of these factors on vaccine uptake may provide a better understanding
for the reasons of lower uptake amongst specific population groups.
Comparison with other studies
Our finding of higher uptake in the main target group compared to the catch-up cohort
reflects the findings from the national annual zoster vaccine coverage data for England over
the same time period, and vaccine coverage among the individuals in our study who were fol-
lowed up for the entire study duration (and thus had fuller capture of uptake of vaccination) is
comparable to the coverage estimates in the national data.[6, 7] Higher uptake amongst males
in the catch-up cohort observed in this study also was shown in the national data for 2013–
2015 for reasons that are currently unexplained.[6, 7] This is in contrast to findings from
North America that have reported a higher zoster vaccine uptake amongst females.[29–31]
The majority of zoster vaccinations (87%) in this study occurred during the influenza season,
suggesting that opportunistic targeting of the eligible population for zoster vaccine during SIV
programme might have played a role. The national annual zoster vaccination data also sup-
ports this finding.[6, 7] Our finding of a linear relationship between increasing level of depri-
vation and lower zoster vaccine uptake also confirms the earlier analyses of the national data,
which found a similar trend but was restricted to examining deprivation at the general prac-
tice-level;[14] studies from the US and Canada have also reported the lower zoster vaccine
amongst individuals with lower income.[30–32] Higher zoster vaccine uptake amongst indi-
viduals of White ethnicity, as seen here, has been reported from other zoster vaccine studies
from high income countries.[14, 30, 32–35]
Several of our findings are novel with respect to zoster vaccine uptake. These include lower
uptake among individuals who were living alone or not cohabiting; this echoes studies show-
ing lower uptake of seasonal influenza vaccine among those living alone in older European
populations.[12] Our finding that immigration status was not independently associated with
zoster vaccine uptake after adjusting for ethnicity is in contrast with previous findings of lower
uptake among immigrant populations for seasonal influenza and pneumococcal vaccine in
Spain and Israel, although none of these studies adjusted additionally for ethnicity.[36–43]
The lower uptake of zoster vaccine among care home residents adds to a number of studies
investigating uptake of other vaccines such as influenza and pneumococcal vaccines which
have reported higher and lower uptake respectively, amongst care home residents.[44–48]
Interpretation of findings and implications
This study demonstrates that in a public funded healthcare system, vaccination inequalities
exist during a crucial period of programme initiation, and identifies socio-demographic
groups that could be targeted with tailored interventions to increase zoster vaccine uptake. Of
particular interest is the finding of lower uptake among care home residents; we have shown
recently that individuals in care homes are at higher risk of developing zoster,[49] and so are a
group with possible double health inequity (of both zoster burden and zoster vaccine uptake).
Lower vaccine uptake among these residents could be due to lack of awareness amongst care
home staff about the newly introduced programme and issues around getting consent. The
reasons cited for differential (higher or lower) uptake of other vaccines among care home resi-
dents have included presence of vaccination polices in care homes, staff awareness, vaccination
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consent from the residents, location and care home ownership (public versus private).[44, 47,
48] The potential double health inequity amongst care home residents highlights a need for
more rigorous targeting of these individuals to mitigate health inequality.
Similarly, targeting of older individuals who live alone may be needed to encourage zoster
vaccination. Individuals cohabiting or living with their relatives may be more motivated by
their social networks to get vaccinated. Secondly, higher disease awareness amongst these indi-
viduals, by witnessing the debilitating effect of zoster in their relatives, may also increase
uptake. This was examined in a US study that reported higher zoster vaccine uptake amongst
individuals in the three months after occurrence of zoster in their partners, reflecting a short
term effect of disease awareness.[50] However, our finding that adjustment for a past personal
history of zoster made little difference to effect estimates of social factors suggests that social
networks may have a longer-lasting effect on encouraging vaccine uptake in older individuals,
or that the occurrence of zoster in partners versus self may have a different effect on uptake.
The lower uptake of vaccine among those of non-White ethnicity, but the attenuation of this
association after restricting to individuals with longer follow up, suggests that there might be
delay in uptake amongst some ethnic groups. There may be a lack of zoster disease awareness
among some ethnic groups because of lower lifetime risk of zoster, which may be due to
genetic causes, social mixing patterns that limit contacts with varicella and thus boosting of
varicella-zoster virus immunity, and late onset of varicella among those born overseas.[33, 50,
51] Alternatively, the lower uptake may reflect existing healthcare inequalities. The lack of
association of immigration status with zoster vaccine uptake after adjusting for ethnicity could
be due to confounding by ethnicity, or simply to lack of power to detect an effect—the number
of individuals identified as immigrants in the study population was relatively small (1.4%;
n = 512) of which zoster vaccine uptake was observed amongst only 229 individuals. It is also
feasible that in England, where national zoster vaccination programme is available free-of-
charge, vaccination inequalities were not observed for older immigrant populations.
Conclusions
This population-based cohort study provides evidence of inequalities in zoster vaccine uptake
in the period immediately after the introduction of a national vaccination programme, identi-
fying a wide range of socio-demographic determinants of uptake of zoster vaccine. This work
should encourage further research into the reasons why specific socio-demographic groups are
less likely to receive zoster vaccine, and effective planning and implementation of specific
interventions to target these socio-demographic groups to mitigate vaccination inequalities
amongst older individuals. Factors that are currently poorly recorded in routinely collected
data, such as religion, education and income, should inform policy drivers such as the sustain-
ability and transformation partnerships to incentivise better recording of these factors and/or
facilitate other data linkages for comprehensive knowledge and future interventions to
improve overall health and wellbeing of older populations. As care home residents are both
less likely to receive zoster vaccine and are at higher risk of zoster, improving the uptake of zos-
ter vaccination in this group will also mitigate inequalities in zoster burden.
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